Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and commercialisation, which will aid clinicians in identifying individuals who may benefit from precision medicines.
This collaboration will leverage the resources of the newly opened Danaher Centers for Enabling Precision Medicine to streamline the development process.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The first product to be developed through this alliance will utilise technologies from Danaher’s subsidiary, Leica Biosystems.
The initial focus will be on creating computational and digital pathology products, as well as AI-assisted algorithms to improve diagnosis and identify patients likely to respond to targeted therapies.
Leica is said to have developed digital pathology solutions and is scaling these technologies for clinical use across its global laboratory network.
To expedite this, Leica has committed to the open-access Digital Imaging and Communications in Medicine (DICOM) standard, promoting interoperability and workflow connectivity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAstraZeneca oncology haematology research and development (R&D) executive vice-president Susan Galbraith said: “The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them.
“Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics, which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress.”
Danaher’s knowledge in science and technology is pivotal for enabling quick diagnoses and decreasing the time and expenses associated with discovering, developing, and delivering the therapies.
In August 2023, Danaher signed an agreement to acquire all outstanding shares of UK-based protein consumables supplier Abcam in a transaction valued at $5.7bn.
